AK

Ashootosh Kumar Mall

Active Director Director DIN 09152159
DIN 09152159 First appointment Apr 2021 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Apr 2021
Shareholding value •••• Premium profile

About Ashootosh Kumar Mall

Data last updated:

Ashootosh Kumar Mall is a Director at City Super Speciality Hospital Private Limited (since 2021), Director at Panacealife Healthzone Private Limited (since 2021) and Director at Jaypar Parenteral Private Limited (since 2026), and holds 1 more current directorship. The companies operate in Healthcare. The 2 current companies with reported revenue have a combined latest revenue of ₹55.67 Cr; the largest is City Super Speciality Hospital Private Limited at ₹49.82 Cr (FY 2025). Earlier, Ashootosh Kumar Mall was a Director at Synergy Institute Of Cancer Care And Research Private Limited (2021–2024).

DIN 09152159
Primary Designation Director
Industry Healthcare
First Appointment 20 Apr 2021
Oldest Company Age 13 yrs
Largest company City Super Speciality Hospital Private Limited · ₹49.82 Cr (FY 2025)
Combined revenue ₹55.67 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director20 Apr 20212021₹49.82 Cr (FY 2025)Active
Director14 Dec 20212013₹5.85 Cr (FY 2025)Active
Jaypar Parenteral Private Limited U21002UP2026PTC250749
Director29 Jul 20262026Active
City Medicity Private Limited U85110UP2021PTC150839
Director18 Aug 20212021Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director11 Oct 20212021₹14.03 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
City Medicity Private Limited
Panacealife Healthzone Private Limited
City Super Speciality Hospital Private Limited
Jaypar Parenteral Private Limited
Premium access

Shareholding and investment profile for Ashootosh Kumar Mall

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ashootosh Kumar Mall

Ashootosh Kumar Mall currently holds 4 directorships: City Super Speciality Hospital Private Limited (Director, since 20 Apr 2021, revenue ₹49.82 Cr (FY 2025)); Panacealife Healthzone Private Limited (Director, since 14 Dec 2021, revenue ₹5.85 Cr (FY 2025)); Jaypar Parenteral Private Limited (Director, since 29 Jul 2026); City Medicity Private Limited (Director, since 18 Aug 2021).

Ashootosh Kumar Mall was first appointed on 20 Apr 2021 as Director at City Super Speciality Hospital Private Limited. The most recent appointment on record is 29 Jul 2026 at Jaypar Parenteral Private Limited.

The 2 current companies of Ashootosh Kumar Mall that report revenue have a combined latest revenue of ₹55.67 Cr: City Super Speciality Hospital Private Limited ₹49.82 Cr (FY 2025); Panacealife Healthzone Private Limited ₹5.85 Cr (FY 2025).

Ashootosh Kumar Mall held 1 earlier board appointment: Synergy Institute Of Cancer Care And Research Private Limited (Director, 11 Oct 2021 to 31 Aug 2024).

The current boards of Ashootosh Kumar Mall's companies include Aishwarya Maddhesia (City Super Speciality Hospital Private Limited), Pragya Ghanshyam Patidar (City Super Speciality Hospital Private Limited), Vimlesh Kumar (City Super Speciality Hospital Private Limited), Alok Tiwari (Panacealife Healthzone Private Limited), Saurabh Mishra (Panacealife Healthzone Private Limited), Jai Kumar Paswan (Jaypar Parenteral Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available